Discussant\u27s response to the case for the unstructured audit approach

https://egrove.olemiss.edu/dl_proceedings/1158/thumbnail.jp

On the Rates of Type Ia Supernovae in Dwarf and Giant Hosts with ROTSE-IIIb

We present a sample of 23 spectroscopically confirmed Type Ia supernovae that were discovered in the background of galaxy clusters targeted by ROTSE-IIIb and use up to 18 of these to determine the local (z = 0.05) volumetric rate. Since our survey is flux limited and thus biased against fainter objects, the pseudo-absolute magnitude distribution (pAMD) of SNeIa in a given volume is an important concern, especially the relative frequency of high to low-luminosity SNeIa. We find that the pAMD derived from the volume limited Lick Observatory Supernova Search (LOSS) sample is incompatible with the distribution of SNeIa in a volume limited (z<0.12) sub sample of the SDSS-II. The LOSS sample requires far more low-luminosity SNeIa than the SDSS-II can accommodate. Even though LOSS and SDSS-II have sampled different SNeIa populations, their volumetric rates are surprisingly similar. Using the same model pAMD adopted in the SDSS-II SNeIa rate calculation and excluding two high-luminosity SNeIa from our sample, we derive a rate that is marginally higher than previous low-redshift determinations. With our full sample and the LOSS pAMD our rate is more than double the canonical value. We also find that 5 of our 18 SNeIa are hosted by very low-luminosity (M_B > -16) galaxies, whereas only 1 out 79 nearby SDSS-II SNeIa have such faint hosts. It is possible that previous works have under-counted either low luminosity SNeIa, SNeIa in low luminosity hosts, or peculiar SNeIa (sometimes explicitly), and the total SNeIa rate may be higher than the canonical value.Comment: 18 pages; accepted for publication in The Astronomical Journa

Principles of Accounting -22/E

As the leader in pedagogical innovation, Principles of Accounting 22 edition, introduce the next step in the evolution of accounting textbooks. Through discussions at the Blue Sky Workshops and other instructor interactions, this edition is closer than ever the becoming the “perfect“ accounting text. To help guide students, the author revised and focused the chapter objectives and developed key learning outcomes related to each chapter objectives. All aspect of the chapter content and end – of – chapter exercises and problems connect back to these objectives and related outcomes. In doing so, student can test their understanding and quickly locate concept to review

An objective approach for Burkholderia pseudomallei strain selection as challenge material for medical countermeasures efficacy testing

Burkholderia pseudomallei is the causative agent of melioidosis, a rare disease of biodefense concern with high mortality and extreme difficulty in treatment. No human vaccines are available that protect against B. pseudomallei infection, and with the current limitations of antibiotic treatment, the development of new preventative and therapeutic interventions is crucial. Although clinical trials could be used to test the efficacy of new medical countermeasures (MCMs), the high mortality rates associated with melioidosis raises significant ethical issues concerning treating individuals with new compounds with unknown efficacies. The US Food and Drug Administration (FDA) has formulated a set of guidelines for the licensure of new MCMs to treat diseases in which it would be unethical to test the efficacy of these drugs in humans. The FDA “Animal Rule” 21 CFR 314 calls for consistent, well-characterized B. pseudomallei strains to be used as challenge material in animal models. In order to facilitate the efficacy testing of new MCMs for melioidosis using animal models, we intend to develop a well-characterized panel of strains for use. This panel will comprise of strains that were isolated from human cases, have a low passage history, are virulent in animal models, and are well-characterized phenotypically and genotypically. We have reviewed published and unpublished data on various B. pseudomallei strains to establish an objective method for selecting the strains to be included in the panel of B. pseudomallei strains with attention to five categories: animal infection models, genetic characterization, clinical and passage history, and availability of the strain to the research community. We identified 109 strains with data in at least one of the five categories, scored each strain based on the gathered data and identified six strains as candidate for a B. pseudomallei strain panel

Bostonia: The Boston University Alumni Magazine. Volume 20

Founded in 1900, Bostonia magazine is Boston University's main alumni publication, which covers alumni and student life, as well as university activities, events, and programs

Vincentiana Vol. 36, No. 1-2 [Full Issue]

+432hlm.;23c

A prospective study of mental health status in morbidly obese patients.

Aim: To determine if co-morbidities have an effect on mood in a cohort of morbidly obese patients

Asociacion del APGAR Familiar y los Valores de Hemoglobina Glicosilada en Pacientes Portadores de Diabetes Mellitus Tipo 2 en los Centro de Salud Carlos Llosa - Hunter y Centro de Salud Edificadores Misti, Arequipa 2018

La diabetes mellitus es una enfermedad crónica prevalente ,según la OMS la prevalencia en adultos mayores de 18 años es de 8,5 % para el 2014. (Salud O. M., 2018) En el Perú el INEI en el 2017 se reportó una prevalencia de 3,3 % en la población adulta mayor a 15 años a nivel nacional. (INEI, 2017).Teniendo esto en cuenta se hace importante entender el funcionamiento familiar para apoyar en el control del paciente diabético y así disminuir los niveles de hemoglobina glicosilada en pacientes portadores de Diabetes Mellitus tipo II que pertenecen a los Centros de Salud Carlos Llosa - Hunter y Edificadores Misti. Y así mejorar el nivel de apoyo l control de enfermedad de esos pacientes y apoyar al Programa de Enfermedades no transmisibles del MINSA y evitar complicaciones crónicas a largo plazo que tienen graves consecuencias no solo para la familia ; sino también a los servicios de salud ya que encarecen los costos de salud. Propósito: El APGAR familiar mide la funcionalidad familiar , esta para el médico familiar es un pilar para el control de múltiples patologías, dentro de ellas la Diabetes Mellitus por tener alta prevalencia de complicaciones en la población general encareciendo los costos de los servicios de salud. El presente trabajo pretende demostrar que uno de los factores más importantes para mejorar el control del paciente diabético que se mide por los niveles de hemoglobina glicosilada es la FUNCIONALIDAD FAMILIAR. Métodos: En el presente trabajo se realizaran visitas domiciliarias A LOS PACIENTES DIABETICOS DENTRO DE LA JURISICCION DE LOS los Centros de Salud Carlos Llosa - Hunter y Edificadores Misti EMPADRONADOS EN EL Programa de Daños no Transmisibles (DANT) , luego De firmaran los consentimientos informados Se procederá a la toma de la hemoglobina glicosilada en sangre y a la aplicación de CUESTIONARIO DE APGAR FAMILIAR , luego de unos 3 meses se procederá a una segunda visita domiciliaria con un segunda toma de hemoglobina glicosilada en sangre y se compararan los resultados. los consentimientos informados autorizaron su participación en la investigación, serán incluidos en el presente estudio Análisis estadístico: El presente trabajo es un estudio descriptivo, observacional, correlacional, y prospectivo, de la información obtenida con el cuestionario de APGAR FAMILIAR y el valor de hemoglobina glicosilada obtenida de las visitas domiciliarias a pacientes diabéticos de la JURISICCION DE LOS los Centros de Salud Carlos Llosa - Hunter y Edificadores Misti EMPADRONADOS EN EL Programa de Daños no Transmisibles (DANT) para lo cual se utilizara el estadístico chi - cuadrado y Correlación de Pearson PALABRAS CLAVE: Diabetes Mellitus tipo 2, Apgar familiar, Hemoglobina GlicosiladaTrabajo académic

Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities

There are currently several ongoing or planned trials evaluating the efficacy of pre-exposure prophylaxis (PrEP) as a preventative approach to reducing the transmission of HIV. PrEP may prove ineffective, demonstrate partial efficacy, or show high efficacy and have the potential to reduce HIV infection in a significant way. However, in addition to the trial results, it is important that issues related to delivery, implementation and further research are also discussed. As a part of the ongoing discussion, in June 2009, the Bill & Melinda Gates Foundation sponsored a Planning for PrEP conference with stakeholders to review expected trial results, outline responsible educational approaches, and develop potential delivery and implementation strategies. The conference reinforced the need for continued and sustained dialogue to identify where PrEP implementation may fit best within an integrated HIV prevention package. This paper identifies the key action points that emerged from the Planning for PrEP meeting